Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

TAVIPILOT Soft is said to be a ‘world-first’ provision for real-time surgical guidance during TAVI and TAVR procedures.

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

The global heart valve frame market is poised for significant growth over the coming years, driven by factors such as increasing prevalence of cardiovascular ...

At baseline, the mechanical valve group tended to be younger (55.7 vs 65.2) and had less aortic stenois (82.4% vs 89.5%), but ...

LOS ANGELES -- Cardiac surgeons were urged to readjust their attitudes toward the tricuspid valve if they want to keep some ...

Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hrs [IST] ...

The Navitor Vision, Abbott's latest TAVI system, is designed to improve accuracy during implantation and enhance visibility ...

Annual Meeting reveals that mechanical aortic valve replacements (AVRs) provide significant long-term survival benefits for ...